Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month

Boehringer makes significant investment to improve the affordability of and access to its full range of inhaler products for COPD and asthma Expansive program builds on the company’s century-long commitment to patients with respiratory illnesses RIDGEFIELD, Conn., March 7, 2024…